Here are your comprehensive, high-yield NEET PG & INI-CET Pathology Notes - sourced from Robbins & Kumar (Basic Pathology + Pathologic Basis of Disease), Robbins, Cotran & Kumar, and aligned with 2024-2025 exam patterns. Format: mixed bullets + tables throughout.
NEET PG & INI-CET PATHOLOGY - HIGH-YIELD NOTES 2026
Exam tip: Pathology carries ~17-25 questions. Since 2023, questions are increasingly clinical application-based rather than pure recall. Focus on mechanisms, morphology, and clinical correlates.
MODULE 1: CELL INJURY, DEATH & ADAPTATIONS
1.1 Causes of Cell Injury (HINT mnemonic)
| Mnemonic Letter | Cause | Key Example |
|---|
| H | Hypoxia / Ischemia | MI, stroke - most common cause |
| I | Immunologic / Inflammatory | Autoimmune disease |
| N | Nutritional imbalance | Kwashiorkor, obesity |
| T | Toxins | CCl4 (liver), CO poisoning |
| + Physical | Trauma, radiation, temperature extremes | Burns, frostbite |
| + Infectious | Bacteria, viruses, parasites | Any pathogen |
| + Genetic | Mutations, chromosomal anomalies | Sickle cell, Down syndrome |
1.2 Reversible vs Irreversible Cell Injury
| Feature | Reversible | Irreversible |
|---|
| Key change | Cell swelling, fatty change | Membrane rupture, nuclear changes |
| Mitochondria | Swelling, small densities | Large flocculent densities |
| Nucleus | Intact | Pyknosis, karyorrhexis, karyolysis |
| Lysosomes | Intact | Rupture (key to irreversibility) |
| Biochemical key | ATP depletion, Na/K pump fails | Loss of plasma membrane integrity |
"Point of no return" = lysosomal rupture + loss of plasma membrane integrity
1.3 Necrosis vs Apoptosis (VERY HIGH YIELD)
| Feature | Necrosis | Apoptosis |
|---|
| Mechanism | Pathologic, accidental | Physiologic OR pathologic |
| ATP required? | No | YES (energy-dependent) |
| Cell size | Swelling | Shrinkage |
| Plasma membrane | Disrupted | Intact (blebbing) |
| Inflammation | YES (always) | NO (phagocytosed by neighbors) |
| Nucleus | Pyknosis/karyorrhexis/karyolysis | Fragmentation (laddering on gel) |
| Caspases involved? | No | YES (executioner: caspase 3,6,7) |
| DNA | Random degradation | Internucleosomal ladder (180 bp) |
| Biochemical marker | LDH, troponin leak | Annexin V+ (phosphatidylserine flip) |
1.4 Types of Necrosis
| Type | Mechanism | Classic Example | Microscopy |
|---|
| Coagulative | Protein denaturation preserves outline | MI, renal infarct | Ghost cells visible |
| Liquefactive | Enzymatic digestion | Brain infarct, bacterial abscess | Pus formation |
| Caseous | Granulomatous reaction | TB | Cheese-like, acellular debris |
| Fat | Lipase digestion | Acute pancreatitis | Saponification, "chalky white" |
| Gangrenous | Coagulative + liquefactive | Limb ischemia with infection | "Wet gangrene" |
| Fibrinoid | Antibody-antigen complexes in vessel wall | Vasculitis, malignant HTN | Bright pink, refractile |
PYQ favourite: Fat necrosis + acute pancreatitis = calcium soaps (saponification). Fibrinoid necrosis = malignant hypertension, polyarteritis nodosa.
1.5 Apoptosis Pathways
- Intrinsic (mitochondrial): DNA damage, ROS → Bcl-2 family → cytochrome c → apoptosome → caspase 9 → caspase 3
- Bcl-2 = ANTI-apoptotic (overexpressed in follicular lymphoma t(14;18))
- Bax, Bak = pro-apoptotic
- Extrinsic (death receptor): FasL binds Fas (CD95) → DISC → caspase 8 → caspase 3
- Key in: CTL-mediated killing, AIDS (CD4+ depletion)
- Both converge on caspase 3
1.6 Cellular Adaptations
| Adaptation | Definition | Example |
|---|
| Hypertrophy | Increase in CELL SIZE (no new cells) | Cardiac hypertrophy in HTN, uterus in pregnancy |
| Hyperplasia | Increase in CELL NUMBER | Endometrial hyperplasia (estrogen), BPH |
| Atrophy | Decrease in cell size/number | Muscle disuse, denervation, aging |
| Metaplasia | One cell type replaced by another (REVERSIBLE) | Columnar → Squamous (Barrett's, smoker's bronchus) |
| Dysplasia | Disordered growth (pre-neoplastic) | CIN, Barrett's with dysplasia |
Key: Metaplasia is reversible; dysplasia may be reversible; neoplasia is irreversible.
1.7 Intracellular Accumulations
| Substance | Condition | Stain |
|---|
| Lipid (triglycerides) | Fatty liver (alcoholism, obesity) | Oil Red O (frozen section) |
| Protein | Russell bodies (plasma cells), Mallory-Denk bodies | H&E (eosinophilic) |
| Glycogen | Diabetes, glycogen storage diseases | PAS stain |
| Hemosiderin | Hemochromatosis, hemorrhage | Prussian blue (Perls stain) |
| Melanin | Melanoma, normal skin | Fontana-Masson |
| Lipofuscin | Aging, wear-and-tear pigment | Brown, perinuclear, autofluorescent |
| Anthracosis | Coal dust (carbon) | Black pigment, no stain needed |
Mnemonic for stains: "Oil Paints Give People More Pleasure Always" - Oil Red O, PAS, Giemsa, Prussian blue, Masson's, Perl's, Alcian blue
MODULE 2: INFLAMMATION
2.1 Acute Inflammation - Key Steps (VLPCE)
- Vascular dilation (arteriolar) - histamine, NO
- Leakage - increased vascular permeability (gaps in venules)
- Pavementing - margination, rolling (selectins), adhesion (integrins: ICAM-1/VCAM-1)
- Chemotaxis - neutrophils migrate (C5a, LTB4, IL-8, bacterial products)
- Elimination - phagocytosis, killing (ROI, NO), resolution
2.2 Chemical Mediators Table (MOST TESTED)
| Mediator | Source | Action | Inhibitor |
|---|
| Histamine | Mast cells, basophils, platelets | Vasodilation, vascular permeability | Antihistamines |
| Serotonin | Platelets | Vasoconstriction/dilation | - |
| PGE2, PGI2 | Arachidonic acid (COX) | Vasodilation, fever, pain | NSAIDs, aspirin |
| LTB4 | AA (5-LOX) | Chemotaxis of neutrophils | Zileuton |
| LTC4, D4, E4 | AA (5-LOX) | Bronchoconstriction, vasopermeability | Montelukast |
| C3a, C5a | Complement | Chemotaxis (C5a), mast cell degranulation | - |
| IL-1, TNF, IL-6 | Macrophages | Fever, acute phase proteins, systemic effects | Steroids |
| IL-8 (CXCL8) | Macrophages, endothelium | Neutrophil chemotaxis | - |
| PAF | Mast cells, leukocytes | Platelet aggregation, permeability | - |
| NO | Endothelium, macrophages | Vasodilation, killing | - |
2.3 Leukocyte Adhesion Molecules
| Step | Molecule | Deficiency |
|---|
| Rolling | P-selectin, E-selectin (endothelial); L-selectin (WBC) | - |
| Firm adhesion | ICAM-1 (endothelial) + LFA-1/Mac-1 (leukocyte) = integrins | LAD (Leukocyte Adhesion Deficiency) = no CD18 (beta-2 integrin) |
| Transmigration | PECAM-1 (CD31) | - |
LAD: Recurrent bacterial infections, NO pus, high blood neutrophils, delayed cord separation. CD18 deficiency.
2.4 Granulomatous Inflammation
- Definition: Chronic inflammation with epithelioid macrophages + Langhans/foreign body giant cells
- Types of granulomas:
| Type | Necrosis | Cause | Key feature |
|---|
| Caseating | YES (caseous necrosis) | TB, deep fungi | AFB stain positive |
| Non-caseating | NO | Sarcoidosis, Crohn's, foreign body, berylliosis, cat scratch | Schaumann/asteroid bodies (sarcoid) |
| "Naked" granuloma | NO | Sarcoidosis | No lymphocytic cuff |
2.5 Outcomes of Acute Inflammation
- Resolution (no damage) → Complete restoration
- Suppuration (pus formation) → Abscess
- Organization (fibrosis) → Scarring
- Chronic inflammation → Persistent stimulus
MODULE 3: NEOPLASIA
3.1 Key Definitions
- Benign: Well-differentiated, encapsulated, no invasion/mets, mitoses rare
- Malignant: Poorly differentiated, invasive, can metastasize, anaplasia
- Anaplasia signs: Pleomorphism, hyperchromatic nuclei, giant cells, abnormal mitoses, loss of polarity
3.2 Tumor Nomenclature
| Tissue | Benign | Malignant |
|---|
| Epithelium (squamous) | Papilloma | Squamous cell carcinoma |
| Epithelium (glandular) | Adenoma | Adenocarcinoma |
| Smooth muscle | Leiomyoma | Leiomyosarcoma |
| Striated muscle | Rhabdomyoma | Rhabdomyosarcoma |
| Bone | Osteoma | Osteosarcoma |
| Cartilage | Chondroma | Chondrosarcoma |
| Fat | Lipoma | Liposarcoma |
| Blood vessels | Hemangioma | Angiosarcoma |
| Melanocytes | Nevus | Melanoma |
| Lymphoid | - | Lymphoma |
| Plasma cells | - | Multiple myeloma |
Exceptions (always malignant by name): Melanoma, hepatoma, seminoma, mesothelioma, glioma
3.3 Oncogenes vs Tumor Suppressors (HIGH YIELD)
| Gene | Type | Tumor Associated | Mechanism |
|---|
| RAS | Proto-oncogene (GTPase) | Pancreas, colon, lung | Gain-of-function mutation |
| MYC | Proto-oncogene (TF) | Burkitt lymphoma (t8;14), SCLC | Amplification/translocation |
| HER2/neu (ERBB2) | Growth factor receptor | Breast, gastric cancer | Amplification |
| BCL-2 | Anti-apoptosis | Follicular lymphoma t(14;18) | Overexpression |
| ABL | Tyrosine kinase | CML t(9;22) Philadelphia chr | BCR-ABL fusion |
| p53 | Tumor suppressor | Almost all cancers; Li-Fraumeni | Loss of function (LOF) |
| RB | Tumor suppressor | Retinoblastoma, osteosarcoma | LOF - both alleles (Knudson 2-hit) |
| APC | Tumor suppressor | FAP, colorectal cancer | LOF |
| BRCA1/2 | Tumor suppressor | Breast, ovarian cancer | LOF |
| VHL | Tumor suppressor | RCC (clear cell), hemangioblastoma | LOF |
| WT1 | Tumor suppressor | Wilms tumor | LOF |
| NF1/NF2 | Tumor suppressor | Neurofibromatosis | LOF |
3.4 Key Translocations (MUST KNOW)
| Translocation | Disease | Fusion / Result |
|---|
| t(9;22) | CML (Philadelphia chr) | BCR-ABL → imatinib target |
| t(8;14) | Burkitt lymphoma | c-MYC near IgH → overexpression |
| t(14;18) | Follicular lymphoma | BCL-2 near IgH → anti-apoptosis |
| t(11;14) | Mantle cell lymphoma | Cyclin D1 near IgH |
| t(15;17) | AML-M3 (APL) | PML-RARα → ATRA therapy |
| t(12;21) | ALL (pediatric, best prognosis) | TEL-AML1 (ETV6-RUNX1) |
| t(4;14), t(14;16) | Multiple myeloma | FGFR3, MAF |
| t(2;5) | Anaplastic large cell lymphoma | NPM-ALK |
| t(X;18) | Synovial sarcoma | SS18-SSX |
| t(11;22) | Ewing sarcoma | EWS-FLI1 |
3.5 Tumor Markers (VERY HIGH YIELD)
| Marker | Tumor | Notes |
|---|
| AFP (alpha-fetoprotein) | HCC, Yolk sac tumor, hepatoblastoma | Also elevated in pregnancy |
| HCG | Choriocarcinoma, gestational trophoblastic disease | Also in normal pregnancy |
| CEA | Colorectal, gastric, lung, breast | Non-specific, used for monitoring |
| PSA | Prostate cancer | Elevated in BPH too |
| CA-125 | Ovarian cancer (serous) | Monitoring recurrence |
| CA 19-9 | Pancreatic cancer | Also cholangiocarcinoma |
| CA 15-3 | Breast cancer | Monitoring |
| S-100 | Melanoma, schwannoma, histiocytoma | Neural crest origin |
| Chromogranin A | Carcinoid, NETs, pheochromocytoma | Neuroendocrine marker |
| NSE | SCLC, neuroblastoma | Neuroendocrine |
| PLAP | Seminoma (dysgerminoma) | Placental alkaline phosphatase |
| Calretinin | Mesothelioma | Also adrenal cortex |
| Desmin | Rhabdomyosarcoma, smooth muscle tumors | Muscle marker |
| Vimentin | Sarcomas (mesenchymal) | Also fibroblasts |
| Keratin (CK) | Carcinomas (epithelial) | Pan-CK for epithelial origin |
3.6 Routes of Metastasis
| Route | Cancer | Example |
|---|
| Lymphatic (most carcinomas) | Breast, GI, lung | Virchow's node (left supraclavicular) = gastric ca |
| Hematogenous (sarcomas, some carcinomas) | Osteosarcoma, RCC | Liver, lung, bone, brain |
| Transcoelomic (seeding) | Ovarian, GI | Krukenberg tumor (gastric → ovary) |
| Perineural | Prostate, pancreas | Nerve sheath invasion |
| Retrograde lymphatic | Prostate, testis | Unusual |
Krukenberg tumor: Signet ring cells (mucin-secreting) metastatic to ovary from stomach/colon; bilateral.
MODULE 4: HEMATOPATHOLOGY
4.1 Anemias Classification
By MCV (Most exam-friendly approach)
Microcytic (MCV < 80) - "TAILS"
- T - Thalassemia
- A - Anemia of chronic disease (can be microcytic/normocytic)
- I - Iron deficiency anemia (most common worldwide)
- L - Lead poisoning
- S - Sideroblastic anemia
Normocytic (MCV 80-100)
- Aplastic anemia
- Hemolytic anemia (acute)
- Anemia of chronic disease
- Renal failure
Macrocytic (MCV > 100)
- Megaloblastic: B12 deficiency, folate deficiency
- Non-megaloblastic: Liver disease, hypothyroidism, drugs (methotrexate, hydroxyurea)
4.2 Iron Deficiency vs Other Microcytic Anemias
| Feature | IDA | Thalassemia | Sideroblastic | ACD |
|---|
| Serum Iron | Low | Normal/High | High | Low |
| TIBC | High | Normal | Normal | Low |
| Ferritin | Low | Normal/High | High | High |
| Serum transferrin saturation | Low | Normal | High | Low |
| Peripheral smear | Hypochromic, microcytic, pencil cells | Target cells, basophilic stippling | Ring sideroblasts (Prussian blue) | - |
| Bone marrow iron | Absent | Present (excess) | Ring sideroblasts | Present |
4.3 Hemolytic Anemias
| Disease | Defect | Test | Notes |
|---|
| Hereditary spherocytosis | Spectrin/ankyrin defect (RBC membrane) | Osmotic fragility test | AD; splenomegaly |
| G6PD deficiency | Enzyme; can't regenerate NADPH | Heinz body (bite cells on Cr stain) | X-linked; triggered by oxidants |
| Sickle cell | HbS (Glu→Val, codon 6, beta chain) | Sickling, Hb electrophoresis | Vaso-occlusion, autosplenectomy |
| PNH | PIGA gene mutation; no CD55/CD59 | Flow cytometry (CD55, CD59) | Hemolysis at night, thrombosis |
| Autoimmune (AIHA) | Warm: IgG; Cold: IgM | Direct Coombs (DAT) | Warm = SLE; Cold = Mycoplasma, EBV |
| Thalassemia | Alpha or beta chain synthesis defect | Hb electrophoresis, HPLC | HbF, HbA2 elevated in beta thal |
4.4 Leukemias (Quick Reference)
| Disease | Age | Cytogenetics | Marker | Key Feature |
|---|
| CML | Middle-aged | t(9;22) Ph+ | BCR-ABL | Basophilia, low LAP score |
| CLL | Elderly (>60) | del(13q), del(11q) | CD5+, CD23+, CD19+ | Smudge cells, Richter transformation |
| ALL | Children (<15) | t(12;21) best; t(9;22) worst | TdT+, CD10+ (CALLA) | Most common childhood leukemia |
| AML-M3 | Any | t(15;17) | MPO+, Auer rods | ATRA treatment, DIC risk |
| Hairy cell | Elderly males | BRAF V600E | CD25+, CD11c+, TRAP+ | Dry tap, splenomegaly, BRAF mutation |
LAP (Leukocyte Alkaline Phosphatase):
- CML = LOW (vs leukemoid reaction = HIGH)
4.5 Lymphomas
Hodgkin Lymphoma (HL)
| Subtype | Reed-Sternberg cell | EBV | Prognosis | Notes |
|---|
| Nodular Sclerosis | Lacunar R-S cell | ~30-40% | Good | Most common; young females; mediastinal mass |
| Mixed Cellularity | Classic R-S (bilobed, "owl eye") | ~70% | Intermediate | EBV most common |
| Lymphocyte Rich | Classic R-S rare | Low | Best prognosis | - |
| Lymphocyte Depleted | Pleomorphic R-S | High | Worst prognosis | HIV patients |
| NLPHL (nodular lymphocyte predominant) | L&H "Popcorn" cell | No | Very good | CD20+, CD15-, CD30- |
Classic HL markers: CD15+, CD30+, CD45-, EMA-
NLPHL: CD20+, CD15-, CD30-
Non-Hodgkin Lymphomas
| Lymphoma | Translocation | Marker | Notes |
|---|
| Follicular | t(14;18) BCL-2 | CD10+, BCL-2+ | Indolent; "waxing/waning" nodes |
| Diffuse Large B cell (DLBCL) | Various | CD20+ | Most common NHL overall |
| Burkitt | t(8;14) MYC | CD10+, TdT- | "Starry sky"; jaw in Africa; sporadic in US |
| Mantle cell | t(11;14) Cyclin D1 | CD5+, CD23- | Aggressive; "mantle zone" pattern |
| Marginal zone (MALT) | H. pylori → gastric MALT | CD5- | Treat with antibiotics first |
| Anaplastic large cell (ALCL) | t(2;5) ALK+ | CD30+, ALK+ | Good prognosis if ALK+ |
4.6 Multiple Myeloma vs Waldenstrom
| Feature | Multiple Myeloma | Waldenstrom's Macroglobulinemia |
|---|
| Immunoglobulin | IgG (most common), IgA | IgM |
| Cells | Plasma cells in bone marrow | Lymphoplasmacytic cells |
| CRAB criteria | Calcium high, Renal failure, Anemia, Bone lesions (lytic) | Hyperviscosity, NO lytic lesions |
| Urine | Bence Jones protein (light chains) | Bence Jones (less common) |
| Rouleaux formation | YES | YES |
| AL amyloidosis | YES | Less common |
| Mutation | KRAS, NRAS, MYC | MYD88 L265P (90%) |
MODULE 5: CARDIOVASCULAR PATHOLOGY
5.1 Atherosclerosis - Key Facts
- Pathogenesis: Response to injury hypothesis (Ross)
- Steps: Endothelial injury → lipid accumulation → monocyte recruitment → foam cells (lipid-laden macrophages) → fatty streak → fibrous plaque → complicated plaque
- Fatty streak = earliest reversible lesion
- Key lipoproteins: LDL - atherogenic (oxidized LDL → foam cells); HDL - protective
- Risk factors: HTN, smoking, diabetes, hyperlipidemia, age, male sex
5.2 Myocardial Infarction - Timeline
| Time | Gross | Microscopy |
|---|
| 0-6 hours | None visible | None (EM: glycogen loss, mitochondrial swelling) |
| 6-12 hours | Subtle pallor | Wavy fibers, coagulative necrosis begins |
| 12-24 hours | Pallor | Pyknosis, contraction bands |
| 24-72 hours | Pale/yellow | Neutrophilic infiltration (max ~48h) |
| 3-7 days | Hyperemic border | Macrophages + granulation tissue begins |
| 1-2 weeks | Yellow center, red border | Granulation tissue, collagen deposition |
| 2-8 weeks | White scar forming | Dense fibrosis |
| >2 months | White fibrous scar | Dense collagen, scar complete |
Earliest light microscopy change (4-12h): Wavy fibers + coagulative necrosis
First inflammatory cells: Neutrophils (12-24h)
Reperfusion injury marker: Contraction band necrosis
5.3 Cardiac Enzymes
| Enzyme | Rises | Peaks | Normalizes | Notes |
|---|
| Troponin I/T | 3-4 h | 12-24 h | 7-14 days | Gold standard; also elevated in PE, myocarditis |
| CK-MB | 4-6 h | 24 h | 48-72 h | Re-infarction marker |
| Myoglobin | 1-2 h | 4-6 h | 24 h | Earliest but non-specific |
| LDH1 | 24 h | 3-6 days | 8-14 days | LDH1>LDH2 = "flipped pattern" in MI |
5.4 Endocarditis
| Feature | Rheumatic | Infective (SBE) | Libman-Sacks (SLE) | Marantic |
|---|
| Vegetation site | Line of closure (atrial side of AV valves) | Irregular, destructive | Both sides of mitral valve | Small, on line of closure |
| Organism | Streptococcus pyogenes | Strep viridans (native), Staph aureus (prosthetic, IVDA) | None (sterile) | None (sterile) |
| Emboli | Rare | Common (septic emboli) | Common | Yes |
| Pathology | Aschoff bodies, verrucous vegetations | Large, irregular, destructive | "Warty" on both surfaces | Thrombotic, non-destructive |
Aschoff bodies: Pathognomonic of rheumatic fever - central fibrinoid necrosis + Anitschkow cells (caterpillar cells = modified macrophages)
MODULE 6: RESPIRATORY PATHOLOGY
6.1 Pneumoconioses
| Disease | Dust | Histology | Complication |
|---|
| Coal workers' (CWP) | Carbon/coal | Coal macules, nodules | Progressive massive fibrosis (PMF) |
| Silicosis | Silica (SiO2) | Silicotic nodules (whorled collagen), "eggshell" calcification of hilar nodes | TB (most important!) |
| Asbestosis | Asbestos fibers | Ferruginous (asbestos) bodies, interstitial fibrosis | Mesothelioma, lung carcinoma |
| Berylliosis | Beryllium | Non-caseating granulomas (mimics sarcoidosis) | Chronic progressive |
Asbestos: MOST carcinogenic pneumoconiosis. Causes: mesothelioma (pleural), adenocarcinoma of lung, peritoneal mesothelioma
6.2 Lung Carcinomas
| Type | Location | Marker | Association | Paraneoplastic |
|---|
| Adenocarcinoma | Peripheral | TTF-1, CK7, Napsin A | Most common overall; EGFR, ALK mutations | Clubbing, hypertrophic osteoarthropathy |
| Squamous cell | Central | CK5/6, p40/p63 | Smoking; cavitation | PTHrP → hypercalcemia |
| Small cell (SCLC) | Central | CD56, Synaptophysin, Chromogranin, NSE | Smoking; WORST prognosis; chemo-sensitive | ADH (SIADH), ACTH (Cushing's), Lambert-Eaton |
| Large cell | Peripheral | None specific | Diagnosis of exclusion | Gynecomastia (HCG) |
| Carcinoid | Central or peripheral | Chromogranin, Synaptophysin | Non-smoking; 5-HT secretion | Carcinoid syndrome (5-HIAA in urine) |
MODULE 7: GIT & LIVER PATHOLOGY
7.1 Gastric Pathology - Quick Facts
- H. pylori: Most common cause of chronic gastritis; Diffuse antral → DU; body gastritis → GU/cancer
- H. pylori → MALT lymphoma (treat with antibiotics + PPI = Regress!)
- H. pylori → type B gastritis (most common type)
- Menetrier disease: Giant mucosal folds, hyperplasia of mucous cells, protein-losing gastropathy, low acid
- Pernicious anemia: Autoimmune gastritis (type A) → anti-parietal cell, anti-intrinsic factor Ab → B12 deficiency → achlorhydria
7.2 Colorectal Cancer - Adenoma-Carcinoma Sequence
Normal epithelium
↓ APC mutation (FAP gene, chromosome 5q)
Aberrant crypt foci / Small adenoma
↓ KRAS mutation
Intermediate adenoma
↓ Loss of 18q (DCC gene)
Late adenoma
↓ p53 mutation (17p)
Carcinoma
↓ Metastasis
Microsatellite instability (MSI) pathway: HNPCC/Lynch syndrome - MLH1, MSH2 defects; right-sided colon cancer; better prognosis
7.3 Liver Pathology
| Condition | Key Feature | Complication |
|---|
| Alcoholic liver disease | Fatty liver → Hepatitis (Mallory-Denk bodies, PMN infiltrate) → Cirrhosis | Portal HTN, HCC |
| NASH | Non-alcoholic; metabolic syndrome, insulin resistance | Same as alcoholic |
| Viral hepatitis | HBV > HCV for HCC | HBV: Ground-glass hepatocytes (HBsAg); HCV: lymphoid aggregates in portal tracts |
| Wilson's disease | ATP7B mutation; copper accumulation | Kayser-Fleischer rings, cirrhosis, neuro symptoms |
| Hemochromatosis | HFE gene; iron overload | "Bronze diabetes" - cirrhosis + diabetes + skin pigmentation |
| Primary biliary cholangitis (PBC) | Anti-mitochondrial Ab (AMA); granulomatous destruction of bile ducts | Pruritus, jaundice, xanthomas |
| Primary sclerosing cholangitis (PSC) | p-ANCA; "onion skin" fibrosis of bile ducts | Cholangiocarcinoma; associated with UC |
7.4 Hepatocellular Carcinoma (HCC)
- Most common primary liver malignancy in adults
- Risk factors: HBV, HCV, Aflatoxin B1 (Aspergillus), Cirrhosis, Alcohol, Hemochromatosis
- AFP elevated (>400 ng/mL highly suggestive)
- Histology: Trabecular pattern, bile production, Mallory-Denk bodies (sometimes)
- Fibrolamellar variant: Young patients, no cirrhosis, better prognosis, AFP normal
MODULE 8: RENAL PATHOLOGY
8.1 Nephritic vs Nephrotic Syndrome
| Feature | Nephritic | Nephrotic |
|---|
| Mechanism | Inflammation, hematuria | Proteinuria (>3.5g/day) |
| Hematuria | YES (RBC casts) | No (or mild) |
| Proteinuria | Mild-moderate | Heavy (>3.5g/day) |
| Edema | Mild | Severe (periorbital, pitting) |
| HTN | YES | Less prominent |
| Lipiduria | No | YES (oval fat bodies, Maltese cross) |
| Examples | RPGN, IgA nephropathy, PSGN | MCD, FSGS, MN, diabetic nephropathy |
8.2 Glomerular Diseases - Quick Summary
| Disease | Mechanism/IF/EM | Clinical | Notes |
|---|
| Minimal change disease (MCD) | No deposits on IF/EM; effacement of foot processes | Nephrotic; Children; responds to steroids | "Minimal" on LM; foot process effacement on EM |
| FSGS | No immune deposits; focal/segmental sclerosis | Nephrotic; Black patients, HIV, heroin | APOL1 gene (African ancestry) |
| Membranous nephropathy (MN) | Subepithelial deposits ("spike and dome"); IgG, C3 | Nephrotic; Adults; "PLA2R" Ab | Most common adult nephrotic |
| MPGN | Subendothelial (Type I) or dense deposits (Type II) | Mixed nephritic-nephrotic | "Tram-track" (Type I); Dense deposit disease (Type II) |
| IgA nephropathy (Berger) | Mesangial IgA deposits | Recurrent gross hematuria after URTI | Most common glomerulonephritis worldwide |
| PSGN | Subepithelial "humps"; IgG, C3; 2-3 wks after Strep | Nephritic; children; low C3, C4 | "Lumpy bumpy" immunofluorescence |
| Goodpasture (anti-GBM) | Linear IgG on GBM | Nephritic + pulmonary hemorrhage | Anti-GBM (type IV collagen) antibodies |
| Lupus nephritis | "Full house" (IgG, IgA, IgM, C3, C1q) | Variable; Class III/IV = aggressive | WHO/ISN-RPS classification |
MODULE 9: REPRODUCTIVE & BREAST PATHOLOGY
9.1 Cervical Pathology
- HPV types: 16, 18 → High risk (carcinoma); 6, 11 → Low risk (condyloma)
- CIN progression: CIN 1 (mild dysplasia, lower 1/3) → CIN 2 (middle 2/3) → CIN 3/CIS (full thickness)
- Koilocytes: HPV-infected cells - perinuclear halo + wrinkled nucleus
- Cervical SCC: Most common (80%); invades locally; radical hysterectomy + radiotherapy
9.2 Ovarian Tumors
| Type | Tumor | Marker | Features |
|---|
| Surface epithelial (70%) | Serous (most common), Mucinous, Endometrioid, Clear cell | CA-125 (serous) | Psammoma bodies (serous); "chocolate cyst" (endometrioma) |
| Germ cell (20%) | Dysgerminoma, Teratoma, Yolk sac, Choriocarcinoma | LDH (dysgerminoma); AFP (YST); HCG (chorio) | Young women |
| Sex cord stromal | Granulosa cell, Sertoli-Leydig | Inhibin | Granulosa = Call-Exner bodies, estrogen → endometrial Ca |
9.3 Breast Pathology
| Condition | Key Feature | Notes |
|---|
| Fibrocystic change | Blue-domed cysts, adenosis, sclerosing adenosis, fibrosis | Non-proliferative = no cancer risk |
| Fibroadenoma | Mobile, rubbery, "mouse" lesion; young women | Most common benign breast tumor |
| Phyllodes tumor | "Leaf-like" clefts, cellular stroma; can be malignant | Large, rapidly growing |
| DCIS | Ductal cells; no basement membrane invasion | Precursor to invasive ductal Ca; comedo type = central necrosis |
| Invasive ductal Ca (NST) | Most common (75%); scirrhous (desmoplastic stroma) | ER/PR/HER2 status determines treatment |
| Invasive lobular Ca | Single-file ("Indian file") pattern; loss of E-cadherin | Bilateral |
| Inflammatory breast Ca | Dermal lymphatic invasion; peau d'orange | Worst prognosis; not a distinct type histologically |
Breast cancer receptor summary:
- Luminal A: ER+/PR+, HER2- (best prognosis)
- HER2+: HER2 amplified, ER- (Trastuzumab target)
- Triple negative: ER-, PR-, HER2- (BRCA1 associated; worst prognosis)
MODULE 10: CNS PATHOLOGY
10.1 CNS Tumors - Classification & High-Yield Facts
| Tumor | Age | Location | Marker | Grade/Notes |
|---|
| Astrocytoma (diffuse) | Adults | Cerebral hemispheres | GFAP+ | IDH1 mutation = better prognosis |
| Glioblastoma (GBM) | Adults >50 | Cerebral hemispheres (butterfly) | GFAP+ | WHO Grade 4; pseudopalisading necrosis; EGFR amplification |
| Oligodendroglioma | Middle-aged | Frontal lobe | GFAP±; IDH+, 1p/19q co-deletion | "Fried egg" cells; calcification; chemo-sensitive |
| Meningioma | Middle-aged women | Parasagittal, sphenoid wing | EMA+, Vimentin+ | Psammoma bodies; NF2 mutation |
| Ependymoma | Children | 4th ventricle (children), spinal cord (adults) | GFAP+ | Perivascular pseudorosettes |
| Medulloblastoma | Children | Posterior fossa / Cerebellum | Synaptophysin+ | Most common malignant pediatric brain tumor; Homer-Wright rosettes |
| Craniopharyngioma | Bimodal (children + elderly) | Suprasellar | Keratin+ | "Motor oil" cyst fluid; calcified; adamantinomatous type |
| Schwannoma | Adults | CN VIII (acoustic) | S-100+; NF2 | Bilateral = NF2 |
| Hemangioblastoma | Adults | Cerebellum | VEGF; VHL mutation | VHL syndrome; "strawberry" cyst |
| Primary CNS lymphoma | Immunosuppressed (HIV, transplant) | Deep white matter, periventricular | CD20+ (DLBCL) | EBV-associated in AIDS |
10.2 Demyelinating Diseases
| Disease | Pathology | Notes |
|---|
| Multiple sclerosis | Plaques of demyelination; periventricular | Dawson's fingers (periventricular plaques); Charcot triad |
| Guillain-Barre syndrome | Ascending motor neuropathy; demyelination | Albuminocytologic dissociation in CSF; post-infectious |
| ADEM | Perivenous demyelination | Post-infectious/vaccination; more diffuse than MS |
MODULE 11: AMYLOIDOSIS
| Type | Protein Precursor | Condition |
|---|
| AL (Primary) | Immunoglobulin light chains | Multiple myeloma, plasma cell dyscrasias |
| AA (Secondary) | SAA (Serum Amyloid A) | Chronic infections (TB, RA, Crohn's) |
| Aβ2M | Beta-2 microglobulin | Long-term dialysis |
| ATTR (Senile/Familial) | Transthyretin | Senile cardiac (wild-type) or familial (mutant) |
| Aβ | APP cleavage → Aβ42 | Alzheimer's disease (senile plaques) |
| Calcitonin-derived | Calcitonin | Medullary thyroid carcinoma |
Diagnosis:
- Congo red stain → apple-green birefringence under polarized light (pathognomonic)
- EM: non-branching fibrils, 7.5-10 nm diameter
- SAP scintigraphy for whole-body distribution
QUICK-REVISION: HIGH-FREQUENCY PYQ FACTS
"First / Most Common / Best" Rapid-Fire
| Fact | Answer |
|---|
| Most common cancer worldwide | Lung cancer (incidence); Breast (female) |
| Most common benign liver tumor | Hemangioma |
| Most common primary malignant liver tumor | HCC |
| Most common cause of cirrhosis worldwide | Viral hepatitis (HCV in West; HBV globally) |
| Most common cause of cirrhosis in India | Alcohol/HBV |
| Most common primary brain tumor | Glioblastoma (GBM) |
| Most common pediatric brain tumor | Astrocytoma (overall); Medulloblastoma (malignant) |
| Most common glomerulonephritis worldwide | IgA nephropathy |
| Most common cause of nephrotic in adults | Membranous nephropathy |
| Most common cause of nephrotic in children | Minimal change disease |
| Most common NHL | Diffuse large B cell lymphoma (DLBCL) |
| Most common Hodgkin lymphoma subtype | Nodular sclerosis |
| Most common leukemia in adults | CLL |
| Most common leukemia in children | ALL |
| Earliest lesion in atherosclerosis | Fatty streak |
| Most carcinogenic pneumoconiosis | Asbestosis |
| Earliest MI change on LM (4-12 h) | Wavy fibers / coagulative necrosis |
| Pathognomonic of TB | Caseating granuloma with Langhans giant cells |
| Psammoma bodies seen in | Papillary thyroid Ca, Serous ovarian Ca, Meningioma, Mesothelioma |
| Most specific test for hemolytic anemia | Direct Coombs (DAT) |
| Philadelphia chromosome found in | CML (and some ALL - bad prognosis) |
| Dry tap in bone marrow | Myelofibrosis, Hairy cell leukemia |
KEY STAINS MASTER TABLE
| Stain | What it shows | Disease/Use |
|---|
| H&E | Universal | All routine histology |
| PAS | Glycogen, fungi, basement membrane | Glycogen storage, GBM thickening |
| Congo red | Amyloid (green birefringence) | Amyloidosis |
| Prussian blue (Perls) | Iron/hemosiderin | Hemochromatosis, sideroblastic anemia |
| Oil Red O | Lipid (frozen section needed) | Fatty liver, lipid pneumonia |
| ZN (Ziehl-Neelsen) | Acid-fast bacilli | TB, atypical mycobacteria |
| Silver (Grocott/GMS) | Fungi | Cryptococcus, Aspergillus, PCP |
| Mucicarmine | Mucin | Cryptococcus capsule, signet ring cells |
| Alcian blue | Acid mucopolysaccharides | Mesothelioma, goblet cells |
| Sudan black | Lipids in leukemia (MPO equivalent) | AML diagnosis |
| MPO (Myeloperoxidase) | Myeloid cells | AML (vs ALL = negative) |
| TdT | Lymphoblasts | ALL (both B and T cell) |
| Fontana-Masson | Melanin | Melanoma |
| Reticulin | Reticular fibers | Myelofibrosis, tumor architecture |
| Masson Trichrome | Collagen (blue) | Cirrhosis, fibrosis |
INI-CET FOCUS: CLINICAL-INTEGRATED PATHOLOGY
Since INI-CET 2023-25 favors clinical application, expect questions like:
- "45-year-old with chronic HCV → cirrhosis → AFP 600 → most likely?" = HCC (know the pathway)
- "Child with painless hematuria + Wilms' tumor → which gene?" = WT1 (11p13)
- "Elderly woman with pathologic vertebral fracture + IgG spike in serum protein electrophoresis?" = Multiple myeloma (think CRAB criteria)
- "Burkitt lymphoma + jaw mass in African child?" = t(8;14), EBV-associated, c-MYC translocation
- "Splenomegaly + low LAP score + basophilia?" = CML, t(9;22)
- "Endocarditis + mitral valve + SLE patient?" = Libman-Sacks (both sides of valve)
- "Reed-Sternberg cell + mediastinal mass + young woman?" = Nodular sclerosis HL
- "Young male + periorbital edema + proteinuria 5g/day + responds to steroids?" = Minimal change disease
- "Congo red + apple green birefringence + chronic RA?" = Secondary (AA) amyloidosis
- "Pancreatitis + hypocalcemia + chalky deposits in mesentery?" = Fat necrosis (saponification)
Source references: Robbins & Kumar Basic Pathology (Robbins Pathology, 9780323790185), Robbins Cotran & Kumar Pathologic Basis of Disease (9780443264528), Goldman-Cecil Medicine, and verified against INI-CET/NEET PG 2024-2025 question patterns.
These notes cover all major pathology modules tested in NEET PG and INI-CET. The shift from 2023 onward is strongly toward mechanism-based clinical vignettes - so always link the pathology to the clinical presentation. Would you like me to create flashcard-style rapid revision sheets, add MCQ practice sets for any specific module, or expand any section (e.g., a full table of paraneoplastic syndromes or a detailed thyroid/adrenal pathology section)?
